Effect of porins and plasmid-mediated AmpC beta-lactamases on the efficacy of beta-lactams in rat pneumonia caused by Klebsiella pneumoniae.

Abstract

The in vivo activities of imipenem, meropenem, and cefepime were studied in a model of rat pneumonia caused by a plasmid-mediated AmpC beta-lactamase ACT-1-producing Klebsiella pneumoniae strain (K. pneumoniae strain 12) and a derivative porin-deficient mutant (K. pneumoniae strain 12dp). No differences between these activities were seen with K. pneumoniae 12. Only meropenem showed an activity slightly better than that of imipenem with K. pneumoniae 12dp.

• Authors: Emma Padilla, Diana Alonso, Antonio Doménech-Sánchez, Cristina Gomez, José Luis Pérez, Sebastián Albertí, Nuria Borrell
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 50 Issue 6 Pg. 2258-60 (Jun 2006) ISSN: 0066-4804 [Print] United States
• PMID: 16723600 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-Bacterial Agents
• Bacterial Proteins
• Cephalosporins
• Porins
• Thienamycins
• beta-Lactams
• Imipenem
• Cefepime
• AmpC beta-lactamases
• beta-Lactamases
• Meropenem

Topics

• Animals
• Anti-Bacterial Agents (pharmacokinetics, pharmacology, therapeutic use)
• Bacterial Proteins (genetics, metabolism)
• Cefepime
• Cephalosporins (pharmacokinetics, pharmacology, therapeutic use)
• Colony Count, Microbial
• Imipenem (pharmacokinetics, pharmacology, therapeutic use)
• In Vitro Techniques
• Klebsiella Infections (drug therapy, microbiology)
• Klebsiella pneumoniae (drug effects, enzymology, genetics)
• Male
• Meropenem
• Microbial Sensitivity Tests
• Plasmids
• Pneumonia, Bacterial (drug therapy, microbiology)
• Porins (deficiency, genetics)
• Rats
• Rats, Wistar
• Thienamycins (pharmacokinetics, pharmacology, therapeutic use)
• Treatment Outcome
• beta-Lactamases (genetics, metabolism)
• beta-Lactams (pharmacokinetics, pharmacology, therapeutic use)